Additional file 2: Figure S2. of Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis

Correlations between platelet activation and markers of inflammation. Correlation between percentage P-selectin expression in all patients (a) and patients with ACPA > 1000 AU/ml (b). Correlation between sCD40L in all patients (c) and patients with ACPA > 1000 AU/ml (d). Correlation between percentage P-selectin expression and RF-IgM in all patients (e) and patients with RF-IgM > 50 IU/ml (f). Correlation between TNF-Îą and P-selectin expression in all patients (g). Correlation between PAF and P-selectin expression in all patients (h). Each symbol represents a plasma sample. (PDF 67 kb

Camptotheca acuminata Decne.

原著和名: カンレンボク科名: ヌマミズキ科 = Nyssaceae採集地: 愛知県 南設楽郡 鳳来町 愛知県林業試験場 (三河 南設楽郡 鳳来町 愛知県林業試験場)採集日: 1985/8/13採集者: 小林元男整理番号: JH026731国立科学博物館整理番号: TNS-VS-976731備考: 旱蓮

Additional file 4: Figure S3. of MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF

BME scores of ACPA-positive patients with RA or UA (n = 123) with low, intermediate, or high levels of ACPA. Horizontal lines represent median. Whiskers show the 10th–90th percentile. Dots represent outliers. Baseline ACPA levels are shown categorically as low, intermediate, or high. The groups were as follows: low ≥7 U/ml, intermediate ≥167 U/ml, and high ≥327 U/ml. Low: n = 57; intermediate: n = 27; high: n = 39. ACPA anti-citrullinated protein antibodies, BME bone marrow edema. Kruskal-Wallis test, p = 0.23. (JPG 19 kb

Enterprise knowledge portals: next-generation portal solutions for dynamic information access, better decision making, and maximum results

Correlation of anti-CarP antibody and ACPA IgM, IgA, and IgG subclasses and RF-IgM with anti-CarP antibody and ACPA IgM in IgG double-positive RA. ELISAs were performed to detect anti-CarP antibody and ACPA isotypes and IgG subclasses in sera of 114 RA patients. Levels of anti-CarP antibodies and ACPAs were plotted against each other, each IgG subclass and isotype separately (A–F). As internal control anti-CarP IgM and ACPA IgM were plotted against RF-IgM (G, H). Spearman Rank tests were performed to investigate correlations. HC; healthy controls, RA; rheumatoid arthritis, ACPA; anti-citrullinated protein antibodies, anti-CarP antibody; anti-carbamylated protein antibody, RF; rheumatoid factor, AU/ml; arbitrary units per millilitre. (TIF 42723 kb

Additional file 2: Figure S1. of Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis

Illustration of a conditional inference tree for developing RA in pre-symptomatic individuals compared with control subjects. CCP2 anti-CCP2 antibodies, Filaggrin anti-filaggrin antibodies, CEP-1 = anti-α-enolase antibodies, IgM-RF immunoglobulin M rheumatoid factor, HLA-SE human leukocyte antigen shared epitope, n number of individuals, Pr probability of detecting a pre-symptomatic individual, + = positive, − = negative. (DOCX 29 kb

Additional file 1: Table S1. of Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis

Prevalence, sensitivity, specificity and OR of numbers of RF isotypes, alone and/or in combination with ten different ACPA specificities, anti-CCP2 antibodies and anti-carbamylated protein antibodies in pre-symptomatic individuals and population controls. (DOCX 17kb

Additional file 1: of Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes

Figure S1. Agreement between previously determined antibody status and remeasurement by ELISA. Figure S2. Overlap of isotypes and antibodies at baseline. Figure S3. DAS over first year of treatment. Figure S4. Initial change in DAS and DFR outcomes within patients positive for individual antibodies. Figure S5. Association between baseline autoantibody profile and long-term sustained drug-free remission within patients that reached early remission and had outcome data available. (DOCX 1605 kb

Additional file 1: of An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting

Diagnosis of anti-CCP-2-negative non-RA patients. Diagnoses of anti-CCP-2-negative non-RA patients (n = 135) as assessed by an experienced rheumatologist after 1 year of follow-up stratified for multiplex positivity. CCP cyclic citrullinated peptide, RA rheumatoid arthritis. (PDF 14 kb

Additional file 2: of An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting

Baseline characteristics of anti-CCP-2-negative RA patients. Baseline characteristics of anti-CCP-2-negative RA patients (n = 279) that are multiplex-negative or -positive. CCP cyclic citrullinated peptide, RA rheumatoid arthritis. (PDF 40 kb

Additional file 6: Figure S6. of The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical

Showing association between age of onset and onset of symptoms within RA patients of the Leiden EAC. (a) Results of logistic regression analyses of age at RA onset in relation to the onset of symptoms. OR of 1.01 indicates that per 1-year increase in the age of onset, the odds of having (sub)acute onset increase 1%. This reflects 12% (1.0110) per 10-year increase in age of onset and 25% (1.0120) per 20-year increase in age of onset. (b) Proportion of RA patients with (sub)acute onset of symptoms in three age groups (p = 0.003). Number of patients per age group: <40, n = 181; 40–60, n = 466; >60, n = 537. (TIF 2476 kb